Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia

Activating D816 mutations of the class III receptor tyrosine kinase KIT are associated with the majority of patients with systemic mastocytosis (SM), but also core binding factor (CBF) AML, making KIT mutations attractive therapeutic targets for the treatment of these cancers. Crenolanib is a potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Kampa-Schittenhelm, Kerstin Maria, Frey, Julia, Haeusser, Lara A., Illing, Barbara, Pavlovsky, Ashly A., Blumenstock, Gunnar, Schittenhelm, Marcus Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669937/
https://www.ncbi.nlm.nih.gov/pubmed/29137311
http://dx.doi.org/10.18632/oncotarget.19970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669937/
https://www.ncbi.nlm.nih.gov/pubmed/29137311
http://dx.doi.org/10.18632/oncotarget.19970

Ejemplares similares